Recent News

• 09.05.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
• 08.28.2025 - Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 05.27.2025 - Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
• 05.20.2025 - Neuphoria Provides First Quarter 2025 Business Updates
• 04.15.2025 - Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
• 03.03.2025 - Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Recent Filings

• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.29.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.18.2025 - 8-K Current report
• 05.20.2025 - EX-99.1 EX-99.1
• 05.20.2025 - 8-K Current report
• 05.20.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.19.2025 - 4/A Statement of changes in beneficial ownership of securities
• 05.15.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.18.2025 - 4 Statement of changes in beneficial ownership of securities